Co-infection of HIV and COVID-19 infection have been described globally, with current estimates (June 2020) putting HIV patients at <1% of COVID-19 cases. The overall case-fatality rate is 14% among HIV-coinfected patients (n = 300), about twice as high than the current rate in the general population though this varies between countries. In contrast to earlier studies regarding HIV co-infection with SARS-CoV-2, this review found that HIV patients on antiretroviral therapy (ART) are not at decreased risk of COVID-19 infection and severe disease progression. Furthermore, after examination of CD4 cell counts, HIV-related immunosuppression does not confer protection by the prevention of cytokine storms and may increase the severity of COVID-19 disease instead.